Plain-English translation of NCT05970237 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is following people who have both type 2 diabetes and high blood pressure as they take dapagliflozin, a medication designed to help manage both conditions. Researchers want to understand how well and safely this medication works in real-world patients. This is an observational study, meaning doctors will monitor your health and medical records rather than testing you in a controlled laboratory setting.
Many people struggle with both high blood pressure and type 2 diabetes at the same time, and treating both conditions together can be challenging. This study exists to learn how well this medication helps manage both problems in everyday patients, so doctors can better understand whether it's a good option for people like you.
You likely qualify if…
You likely don't qualify if…
You will continue taking your prescribed medication as normal—this is not a study where you receive a new experimental treatment. Instead, researchers will check in with you at scheduled visits to monitor your blood pressure, blood sugar levels, and overall health, and review your medical records to see how well the medication is working for you. The study involves approximately 9,000 participants and will track your progress over time to gather real-world evidence about the medication's effectiveness and safety.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
South Korea
Boryung Pharmaceutical Co., Ltd
Enrollment target
~9,000 participants
Started
July 2023
Primary completion
October 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
19 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Shinyoung Oh
Boryung Pharmaceutical Co., Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.